公开(公告)号：US20240101689A1

公开(公告)日：2024-03-28

申请号：US18520650

申请日：2023-11-28

申请人： Boehringer Ingelheim International GmbH

发明人： Rolf HERRMANN ,  Remko Alexander BAKKER ,  Sebastian BANDHOLTZ ,  Peter Michael BENZ ,  Michael DZIEGELEWSKI ,  Lore Katharina FLORIN ,  Cynthia Hess KENNY ,  Sarah Kathleen LOW ,  Holger ROSENBROCK ,  Sanjaya SINGH ,  Heiko Friedrich STAHL ,  Sathyadevi VENKATARAMANI ,  Vladimir H. VOYNOV ,  Haiguang XIAO

IPC分类号： C07K16/28 ,  A61P25/28

CPC分类号： C07K16/2863 ,  A61P25/28 ,  A61K2039/505 ,  C07K2317/56 ,  C07K2317/565

摘要： The present invention relates to novel agonistic anti-TrkB antibodies and therapeutic and diagnostic methods and compositions for using the same.

公开(公告)号：US20210267947A1

公开(公告)日：2021-09-02

申请号：US17251576

申请日：2019-06-28

申请人： Boehringer Ingelheim International GmbH

发明人： Armin HECKEL ,  Robert AUGUSTIN ,  Sebastian BANDHOLTZ ,  Sara FRATTINI ,  Bernd WELLENZOHN

IPC分类号： A61K31/4192 ,  C07D403/04

摘要： The present invention relates to compounds of general formula I, wherein the groups R1, R2, R3, R4, n and m are as defined herein, which have valuable pharmacological properties, in particular bind to the GPR142 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as type 2 diabetes.